

July 17, 2026

Honorable James Comer
Chairman

Honorable Robert Garcia
Ranking Member

Committee on Oversight and Government Reform
U.S. House of Representatives Washington, DC 20515

RE: Support for H.R. 6610, the Pharmacists Fight Back Act [in Federal Employee Health Benefits Program Act]

Dear Chairman Comer, Ranking Member Garcia, and Members of the Committee:

Representing a broad national coalition of healthcare providers, small business owners, patient advocates, and consumer advocates, we write to thank the Committee for its robust work exposing anti-competitive pharmacy benefit manager (PBM) practices over the last several years, and to strongly urge the Committee's swift consideration and passage of H.R. 6610. We are grateful to Chairman Comer for his direct leadership as a co-lead of this vital legislation. With 36 bipartisan cosponsors, including 11 distinguished members of this Committee, the robust support for H.R. 6610 reflects strong momentum for the meaningful reforms it contains.

The House Committee on Oversight and Reform has been an integral part of exposing problematic PBM practices including, without limitation, rebate games, patient steering, and unsustainable reimbursements to retail pharmacies. In addition to the work of this Committee, the Federal Trade Commission (FTC) has issued two Section 6(b) study interim reports alongside numerous state-level audits regarding PBM practices more broadly.

While Congress has taken meaningful action on PBM reform in Medicare Part D and the commercial market through the 2026 Consolidated Appropriations Act, PBM practices within the Federal Employees Health Benefits Program (FEHBP), one of the largest employer-sponsored health programs in the nation, covering over 8 million beneficiaries, remain largely unaddressed.

Importantly, recent Office of Personnel Management (OPM), Office of the Inspector General (OIG) audits of PBM practices within the FEHBP uncovered significant discrepancies and a pattern of PBM overcharges, including:

- Identified \$493 million in PBM overcharges, including \$400.7 million in retail pharmacy discounts and \$92.4 million in retail pharmacy transmission fees withheld from the plan.¹
- Identified \$40 million in PBM overcharges including from the PBMs failure to pass-through retail pharmacy discounts and drug manufacturer rebates/discounts paid to the PBM and its offshore sister company.²
- Uncovered \$16.4 million in PBM overcharges including from the PBMs failure to pass-through retail pharmacy discounts, and drug manufacturer rebates from its offshore sister company.³
- Identified \$6.9 million in PBM overcharges from the PBMs failure to pass-through retail pharmacy transmission fees.⁴

Taken together, these plan-specific OIG audits, combined with broader nationwide findings of systematic under-reimbursement of community pharmacies and artificial markups at PBM-owned specialty pharmacies, **underscore the urgent need to address non-transparent PBM drug pricing practices across all pharmacy channels**. Ultimately, these findings reveal that PBMs are leveraging their positions as federal subcontractors within the FEHBP to benefit themselves and their affiliates to the detriment of patients, taxpayers, and non-affiliate community pharmacies. H.R. 6610 directly addresses these exact vulnerabilities and restores integrity to prescription drug pricing within the FEHBP through three core pillars:

1. Establishing transparent, market-based pricing via a NADAC + 4% + professional dispensing fee model, which will bring underwater pharmacy claims up to a sustainable rate while capping PBM overcharges at their own affiliated pharmacies.
2. Prohibiting post-adjudication pharmacy adjustments and point of sale pharmacy fees, explicitly cutting off the ability of PBMs to extract hidden fees and effectively ending predatory "spread pricing" games.
3. Mandating a 100% pass-through of all manufacturer rebates, including those funneled through offshore GPOs, directly back to beneficiaries to ensure lower drug prices at the pharmacy counter.

¹ Report # 2024-SAG-013: https://www.oversight.gov/sites/default/files/documents/reports/2026-03/2024-SAG-013_0.pdf.

² Report # 2022-SAG-029: <https://www.oversight.gov/sites/default/files/documents/reports/2024-10/2022-SAG-029.pdf>.

³ Report # 2023-SAG-019: <https://www.oversight.gov/sites/default/files/documents/reports/2025-01/2023-SAG-019.pdf>.

⁴ Report # 2024-SAG-022: <https://www.oversight.gov/sites/default/files/documents/reports/2025-12/2024-SAG-022.pdf>.

Additionally, H.R. 6610 contains strong anti-steering provisions protecting patient choice of pharmacy provider, robust transparency reporting mandates, and strict civil penalties to serve as an effective deterrent.

The foregoing provisions will help protect community pharmacies from predatory contracting, shield federal enrollees from forced steering, and restore free market principles and fiscal accountability to a program that accounts for tens of billions in taxpayer dollars annually. By restructuring these incentives, H.R. 6610 will directly lower out-of-pocket costs for federal beneficiaries at the pharmacy counter while putting an end to the PBM overcharges that inflate premiums for employees and taxpayers alike.

H.R. 6610 provides the statutory teeth needed to stop these systemic PBM abuses and ensure that the FEHBP finally operates with the transparency and fairness that federal employees and American taxpayers deserve.

For these reasons, we strongly urge the Committee to swiftly pass H.R. 6610, the Pharmacists Fight Back Act. Thank you for your continued leadership and dedication to healthcare transparency.

Sincerely,

National Community Pharmacists Association
National Alliance of State Pharmacy
Associations
Pharmacists United for Truth & Transparency

American Pharmacies
American Pharmacy Cooperative Inc
Compliant Pharmacy Alliance Cooperative
EPIC Rx
Independent Pharmacy Cooperative
Independent Pharmacy Alliance
Sav-Mor Pharmacy Services

American Economic Liberties Project
Global Healthy Living Foundation
Pioneer Institute
Local First Arizona
Minnesota Farmers Union

Advocates for Responsible Care
Rx in Reach Georgia Coalition
Unite for Safe Medications
Arizona Desert Life Pharmacy Patients
Organization

Alabama Independent Pharmacy Alliance
Alabama Pharmacy Association
Arizona Independent Pharmacy Coalition
Arizona Pharmacy Association
Arkansas Pharmacists Association
California Pharmacists Association
Colorado Pharmacists Society
Connecticut Pharmacists Association
Delaware Pharmacy Society
Florida Pharmacy Association
Florida Small Business Pharmacies Aligned
for Reform
Georgia Academy of Independent Pharmacy
Georgia Pharmacy Association
Illinois Pharmacists Association
Indiana Pharmacy Association
Kansas Pharmacists Association
Kentucky Independent Pharmacists Alliance
Kentucky Pharmacists Association
Louisiana Independent Pharmacies
Association
Maryland Pharmacists Association
Massachusetts Pharmacists Association
Michigan Independent Pharmacy Association

Michigan Pharmacists Association
Minnesota Independent Pharmacy Association
Mississippi Independent Pharmacy
Association
Mississippi Pharmacists Association
Missouri Pharmacy Association
Missouri Pharmacy Business Council
Montana Pharmacy Association
Nebraska Pharmacists Association
Nevada Pharmacy Alliance
New Mexico Pharmacy Association
North Carolina Association of Pharmacists

Ohio Pharmacists Association
Pharmacists Society of the State of New York
SIP for PBM Reform
South Carolina Pharmacy Association
Tennessee Pharmacists Association
Texas Pharmacy Association
Virginia Pharmacy Association
Washington DC Pharmacy Association
Washington State Pharmacy Association
West Virginia Independent Pharmacy
Association